1. Home
  2. ONC vs AEE Comparison

ONC vs AEE Comparison

Compare ONC & AEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • AEE
  • Stock Information
  • Founded
  • ONC 2010
  • AEE 1901
  • Country
  • ONC Switzerland
  • AEE United States
  • Employees
  • ONC N/A
  • AEE N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • AEE Power Generation
  • Sector
  • ONC Health Care
  • AEE Utilities
  • Exchange
  • ONC Nasdaq
  • AEE Nasdaq
  • Market Cap
  • ONC 26.9B
  • AEE 26.0B
  • IPO Year
  • ONC N/A
  • AEE N/A
  • Fundamental
  • Price
  • ONC $250.30
  • AEE $96.53
  • Analyst Decision
  • ONC Strong Buy
  • AEE Buy
  • Analyst Count
  • ONC 9
  • AEE 11
  • Target Price
  • ONC $325.56
  • AEE $100.91
  • AVG Volume (30 Days)
  • ONC 345.1K
  • AEE 1.7M
  • Earning Date
  • ONC 08-06-2025
  • AEE 07-31-2025
  • Dividend Yield
  • ONC N/A
  • AEE 2.95%
  • EPS Growth
  • ONC N/A
  • AEE 3.54
  • EPS
  • ONC N/A
  • AEE 4.51
  • Revenue
  • ONC $4,175,868,000.00
  • AEE $7,596,000,000.00
  • Revenue This Year
  • ONC $869.15
  • AEE $13.04
  • Revenue Next Year
  • ONC $19.07
  • AEE $5.42
  • P/E Ratio
  • ONC N/A
  • AEE $21.36
  • Revenue Growth
  • ONC 51.16
  • AEE 9.04
  • 52 Week Low
  • ONC $146.21
  • AEE $71.87
  • 52 Week High
  • ONC $287.88
  • AEE $104.10
  • Technical
  • Relative Strength Index (RSI)
  • ONC N/A
  • AEE 51.36
  • Support Level
  • ONC N/A
  • AEE $94.20
  • Resistance Level
  • ONC N/A
  • AEE $96.46
  • Average True Range (ATR)
  • ONC 0.00
  • AEE 1.27
  • MACD
  • ONC 0.00
  • AEE 0.11
  • Stochastic Oscillator
  • ONC 0.00
  • AEE 74.71

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

About AEE Ameren Corporation

Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas in Missouri and Illinois. It serves 2.5 million electricity customers and approximately 1 million natural gas customers.

Share on Social Networks: